Discover how the Post-PCI Corrected TIMI Frame Count, a pivotal measure in cardiology, can predict heart function recovery after a severe heart attack, offering new insights from the MIRTOS study.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Post-PCI corrected TIMI Frame Count predicts left ventricular global longitudinal strain at 90 days post-STEMI in thrombolysis-treated patients: A pre-specified analysis of the MIRTOS study.
Anastasiou et al., Am Heart J Plus 2022
<!– DOI: 10.1016/j.ahjo.2022.100222 //–>
https://doi.org/10.1016/j.ahjo.2022.100222
In a detailed analysis within the MIRTOS trial, researchers explored the impact of ticagrelor versus clopidogrel, alongside thrombolysis, on left ventricular systolic function recovery in ST-segment elevation myocardial infarction (STEMI) patients. The study focused on changes in left ventricular ejection fraction (ΔLVEF) and left ventricular longitudinal strain (ΔLV-GLS) over 90 days. Results showed no significant difference in myocardial recovery between the ticagrelor and clopidogrel groups (ΔLVEF: +3.61% vs. +2.21%, P=0.18; ΔLV-GLS: -1.53% vs. -1.21%, P=0.73). However, a notable finding was the strong negative correlation between post-percutaneous coronary intervention (PCI) corrected TIMI Frame Count (CTFC) and LV-GLS at 90 days (r=-0.33, P=0.014), indicating that post-PCI microvascular integrity could predict left ventricular systolic function recovery in STEMI patients treated initially with thrombolysis. This study underscores the comparable efficacy of ticagrelor and clopidogrel in myocardial recovery post-thrombolysis and highlights the predictive value of post-PCI CTFC in assessing myocardial recovery.